• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corp (NQ: INCY )

    75.87 -1.86 (-2.39%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Incyte Corp

    < Previous 1 2 3 4 5 6 Next >
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
    From Incyte
    Via Business Wire
    Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
    From Incyte
    Via Business Wire
    Incyte to Report Third Quarter Financial Results
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
    From Incyte
    Via Business Wire
    Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
    From Incyte
    Via Business Wire
    Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
    From Incyte
    Via Business Wire
    Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
    From Incyte
    Via Business Wire
    Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
    From Incyte and Syndax Pharmaceuticals
    Via Business Wire
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Incyte Announces Final Results of Tender Offer
    From Incyte Corporation
    Via Business Wire
    Incyte Announces Preliminary Results of Tender Offer
    From Incyte Corporation
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    Incyte Completes Acquisition of Escient Pharmaceuticals
    From Incyte
    Via Business Wire
    Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
    From Incyte
    Via Business Wire
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
    From Incyte
    Via Business Wire
    Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
    From Incyte Corporation
    Via Business Wire
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.